At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 134 enrolled
Drug / intervention
Pitavastin 4mg +2 moredrug
Likely dose
Pitavastin 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)
In Brief
A Phase 4 clinical trial evaluating Pitavastin 4mg, Atorvastatin 20mg, and 1 other intervention for Hypercholesterolemia. Completed, enrolled 134 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
CollaboratorsKowa Pharmaceuticals America, Inc., Eli Lilly and Company
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedAug 2012
Primary CompletionAug 2013
Study CompletionOct 2013
TodayJul 2026
First PostedAug 8, 2012
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.9 years ago
Interventions
Pitavastin 4mgdrug
Atorvastatin 20mgdrug
Rosuvastatin 5mgdrug